Camber Pharmaceuticals Inc
Crystal Mechler has extensive work experience in the pharmaceutical industry, with a focus on national accounts. Crystal held the position of Director of National Accounts at Camber Pharmaceuticals Inc starting in December 2018. Prior to that, they worked at Aurobindo Pharma USA, Inc. from May 2015 to November 2018, and at Trigen Laboratories from August 2012 to May 2015, both in the role of Director of National Accounts. From November 2004 to July 2012, Crystal worked at Boca Pharmacal, Inc. as a National Account Manager. Crystal began their career at NBTY as a Sales Rep, where they worked from September 1999 to November 2004.
Crystal Mechler earned a Bachelor of Science (B.S.) degree in Dietetics from Florida State University, where they studied from 1993 to 1999. Crystal then pursued a Master of Science (M.S.) degree in Clinical Nutrition at Rosalind Franklin University of Medicine and Science from 2004 to 2006. Prior to their higher education, Crystal attended Hallandale High, although specific dates and degrees are not provided.
This person is not in any offices
Camber Pharmaceuticals Inc
Camber is made up of three groups with one common goal: to be the best generics company in the industry. Camber Pharmaceuticals is rapidly growing and had an industry-leading 28 product approvals in 2022. With the support of our parent company, Hetero, we are poised to have a record number of product approvals and launches in 2023. Hetero, a world leader in API production and vertical manufacturing, is the foundation upon which Camber has maintained a 99% service level for our customers for the past two years. Hetero is investing over $250 million in the next three years in Camber products. The research and development team consists of over 1,000 scientists working to expand the types of drugs Camber offers, including novel delivery systems and complex molecules.